
April 21 (Reuters) - AstraZeneca PLC AZN.L:
ENHERTU® (FAM-TRASTUZUMAB DERUXTECAN-NXKI) PLUS PERTUZUMAB DEMONSTRATED HIGHLY STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENT IN PROGRESSION-FREE SURVIVAL VERSUS. THP AS 1ST-LINE THERAPY FOR PATIENTS WITH HER2+ METASTATIC BREAST CANCER